

### REMARKS

In response to the Restriction Requirement mailed April 20, 2004, Applicants elect Group II, claims 5-14, 30, 33, and 42-53, drawn to an isolated nucleic acid molecule, variants, fragments, and complements thereof; vectors, cells, pharmaceutical compositions and kits containing same, classified in class 435, subclass 69.1, 320.1, 252.3; and class 536, subclass 23.5. Further, applicants elect the nucleic acid sequence of SEQ ID NO:210, encoding the polypeptide of SEQ ID NO: 211. The elections are made without traverse.


Upon entry of this amendment, claims 42-53, and 60-64 will be pending. Claims 1-41, and 54-59 have been canceled without prejudice or disclaimer as drawn to non-elected subject matter. Applicants reserve the right to pursue these claims in later filed applications. Support for new claim 60-64 is found throughout the Specification and claims as filed. No new matter has been added.

### CONCLUSION

On the basis of the foregoing amendments and remarks, Applicants respectfully submit that this paper is fully responsive and that the pending claims are in condition for allowance. Such action is respectfully requested. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

Dated: May 20, 2004

for:  Reg. No. 48,128  
Ivor R. Elrifi, Reg. No. 39,529  
Attorney for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
Customer No. 30623.